title: [Enantiomers: a new problem in pharmacotherapy of depression?].
abstract: Enantiomers as a optically active forms of drugs now have a big impact on most areas of pharmacotherapy. They arouse a large interest in the field of psychiatry and especially in the treatment of depression. This is due to the fact that enantiomers (chiral forms) of many drugs may have a different pharmacokinetic, pharmacological or pharmacogenetic profiles. Therefore, in many cases the use of a single enantiomer of the drug may have huge advantages over previously used forms and lead to strong improvement of the current treatments. An example is the stereoselective property of such a psychotropic drug fluoxetine as belonging to a group of selective serotonin reuptake inhibitors (SSRI).
authors.affiliation: Katedra i Zakład Biochemii i Chemii Klinicznej, Warszawskiego Uniwersytetu Medycznego.
authors.forename: Błazej
authors.initials: B
authors.lastname: Grodner
authors.forename: Dariusz
authors.initials: D
authors.lastname: Sitkiewicz
mesh_terms: D000928:Antidepressive Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy*; D003866:Depressive Disorder / Q000188:drug therapy*; D005473:Fluoxetine / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D011619:Psychotropic Drugs / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D005473:Fluoxetine; D011619:Psychotropic Drugs; D017367:Selective Serotonin Reuptake Inhibitors